miR-128-3p Reduces Proliferation and Immune Escape in Acute Myeloid Leukemia Through Targeted Regulation of ZEB1
- PMID: 40381097
- DOI: 10.1007/s12010-025-05255-8
miR-128-3p Reduces Proliferation and Immune Escape in Acute Myeloid Leukemia Through Targeted Regulation of ZEB1
Abstract
microRNAs have received wide attention as potential therapeutic targets. This study explored the action of miR-128-3p in acute myeloid leukemia (AML). miR-128-3p expression in AML was determined by quantitative PCR method. MTT proliferation assay and immunoblot assay were employed to detect proteins related to proliferation and apoptosis in THP-1 cells overexpressing miR-128-3p. RNA immunoprecipitation and dual luciferase reporting system were utilized to verify downstream targets of miR-128-3p. Flow cytometry was conducted to analyze the apoptosis rate and immune escape of THP-1 cells in the T-cell co-culture system. miR-128-3p was lowly expressed in AML patients (reduced by 41.6%). Overexpression of miR-128-3p inhibited THP-1 cell proliferation and immune escape, and stimulated apoptosis. ZEB1 was a downstream target of miR-128-3p, and up-regulation of miR-128-3p inhibited ZEB1 mRNA and protein expression (respectively reduced by 65.8% and 42.0%). Upregulating ZEB1 reversed the inhibitory effect of upregulating miR-128-3p on THP-1 cell proliferation and immune escape. Upregulating ZEB1 promoted PD-L1 protein expression (increased by 0.75-fold). Blocking PD-L1 reversed the promotion of THP-1 cell proliferation and immune escape by upregulating ZEB1. The miR-128-3p/ZEB1/PD-L1 axis is involved in regulating the proliferation and immune escape of AML cells, providing new insights into the molecular mechanism of miR-128-3p in AML and, more importantly, a new target for immunotherapy of AML.
Keywords: Acute myeloid leukemia; PD-1; PD-L1; ZEB1; miR-128-3p.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Ethics Statement: The present study was approved by the Ethics Committee of Peking Union Medical College Hospital (No.201302BJ24) and written informed consent was provided by all patients prior to the study start. All procedures were performed in accordance with the ethical standards of the Institutional Review Board and The Declaration of Helsinki, and its later amendments or comparable ethical standards. The animal experiment research protocol was approved by the Ethics Committee of Peking Union Medical College Hospital (No.2012-BJ105) and performed in accordance with the “Guidelines for the care and use of experimental animals.” Consent to Publish: Written informed consent for publication was obtained from all participants. Consent to Participate: Written informed consent was obtained from each subject. Conflict interests: Authors declared no conflict of interest.
Similar articles
-
miR-186-5p Down-Regulates PD-L1 Level in Acute Myeloid Leukemia Cells and Inhibits Tumorigenesis and Immune Escape.J Biochem Mol Toxicol. 2025 May;39(5):e70278. doi: 10.1002/jbt.70278. J Biochem Mol Toxicol. 2025. PMID: 40285500
-
CircAGFG1 Promotes Ovarian Cancer Progression Through the miR-409-3 p/ZEB1 Axis.Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241252423. doi: 10.1177/15330338241252423. Technol Cancer Res Treat. 2024. PMID: 38752261 Free PMC article.
-
Shikonin inhibits epithelial-mesenchymal transition in glioblastoma cells by upregulating p53 and promoting miR-361-5p level to suppress ZEB1 expression.BMC Neurosci. 2025 Jul 1;26(1):37. doi: 10.1186/s12868-025-00956-6. BMC Neurosci. 2025. PMID: 40597639 Free PMC article.
-
A Novel circ_0104345/miR-876-3p/ZBTB20 Axis Regulates the Proliferation, Migration, Invasion, and Apoptosis of Breast Cancer Cells.Biochem Genet. 2023 Dec;61(6):2548-2565. doi: 10.1007/s10528-023-10391-z. Epub 2023 May 6. Biochem Genet. 2023. PMID: 37148331
-
Immunosuppressive cells in acute myeloid leukemia: mechanisms and therapeutic target.Front Immunol. 2025 Jul 23;16:1627161. doi: 10.3389/fimmu.2025.1627161. eCollection 2025. Front Immunol. 2025. PMID: 40771826 Free PMC article. Review.
References
-
- Taghiloo, S., & Asgarian-Omran, H. (2021). Immune evasion mechanisms in acute myeloid leukemia: A focus on immune checkpoint pathways. Critical Reviews in Oncology Hematology, 157, 103164. - PubMed
-
- Wang, H., He, H., & Yang, C. (2019). miR-342 suppresses the proliferation and invasion of acute myeloid leukemia by targeting Naa10p. Artificial Cells, Nanomedicine, and Biotechnology, 47, 3671–3676. - PubMed
-
- Deng, L., Jiang, L., Lin, X. H., Tseng, K. F., Liu, Y., Zhang, X., Dong, R. H., Lu, Z. G., & Wang, X. J. (2017). The PI3K/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia. Acta Pharmacologica Sinica, 38, 382–391. - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials